Glenmark USA to Launch Leucovorin Injection in December 2025
💊 GLENMARK Inc., USA will launch Leucovorin Calcium for Injection USP (350 mg/vial) in December 2025. The product is bioequivalent to Hospira’s reference drug and targets an annual market size of $16.8 million, strengthening Glenmark’s oncology-supportive care portfolio.
#FundamentalViews#Pre-OpeningCommentary
984 likes·67 comments